Metastatic Prostate Cancer
Metastatic Prostate Cancer occurs when prostate cancer spreads from the prostate gland to other parts of the body, such as bones or lymph nodes, often leading to more severe symptoms and complications.
Prostate Cancer: ADT with Darolutamide
We are studying whether adding darolutamide to standard hormone therapy helps frail men with newly diagnosed metastatic prostate cancer live longer and feel better. This trial compares the new treatment to a placebo to assess its effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have prostate cancer that has been confirmed by a doctor?
- Have you had any major surgery in the last 28 days?
- Do you have uncontrolled high blood pressure (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg)?
- Do you have any serious health problems that are not under control?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Bay 1841788
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Grand Hopital De Charleroi
Oncology
Charleroi, Belgium
Pole Hospitalier Jolimont
Oncology
Fayt-lez-Manage, Belgium
Clinique Saint-Pierre
Oncology
Ottignies, Belgium
Sponsor: Unicancer
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.